Psychedelics · 2021
Psychedelic Harm Reduction and Integration (PHRI)
Integration occurs when the psychedelic experience is explored without judgement, contextualised safely and its meanings embodied in everyday life.
Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical, transdiagnostic clinical framework formalised in 2021 by Ingmar Gorman and Elizabeth M. Nielson, with Aja Molinar, Ksenia Cassidy and Jonathan Sabbagh as co-authors of the founding publication, for working psychotherapeutically with people who use, have used or are considering using psychedelics in clinical, spiritual, community, recreational or self-directed contexts. PHRI integrates principles from Integrative Harm Reduction Psychotherapy, psychedelic-assisted psychotherapy, mindfulness-based approaches and psychodynamic-relational theory, and adopts a compassionate, non-stigmatising, non-hierarchical stance centred on autonomy: the therapist explores the person's actual relationship with psychedelics, their motives, risks, benefits, expectations and context, without presuming addiction or imposing abstinence. The framework may begin before an experience, through preparation, psychoeducation, clarification of motivations, risk assessment, management of expectations and planning for re-entry, or after the experience has ended, working with whatever the person brings back — insight, fear, confusion, disappointment, traumatic experiences, ego dissolution, spiritual change, heightened sensitivity or an altered sense of their life. The PHRI therapist neither prescribes nor administers the psychedelic, does not encourage its use and does not provide therapy during the acute psychedelic state; their task is to reduce harm, sustain a non-directive, inner-directed exploration, foster curiosity and acceptance towards the experience, discriminate when distress can be addressed psychotherapeutically and when it requires a higher level of care, and help to translate meanings and insights into sustainable changes in body, behaviour, values, relationships and everyday life. PHRI can be incorporated into brief encounters as well as into ongoing psychotherapy and can accompany people who additionally present with depression, anxiety, PTSD or other trauma-related difficulties, although the framework is transdiagnostic and does not in itself constitute an established treatment specific to those disorders; the published formulation focuses mainly on individual clinical encounters and may draw on community or group resources, but it does not manualise a group protocol of its own. Its specific evidence remains preliminary: the founding article acknowledges a scarcity of direct empirical evidence for PHRI and calls for efficacy studies, while the available research mainly supports related components — harm reduction, safety, integration, alliance, mindfulness and processes in psychedelic-assisted psychotherapy — so that the results of trials involving the administration of psychedelics should not be attributed automatically to PHRI.
Theory of change
The person changes when they can relate to their psychedelic experience with greater safety, curiosity and autonomy, build a meaning of their own and translate it into sustainable actions that reduce harm and increase coherence in their life.
Core ideas
-
PHRI organises preparation and integration without administering the psychedelic
The boundary that defines PHRI is clinical and ethical: the model allows work with people who are considering using, are using or have used psychedelics, but excludes prescribing, administering and supplying the compound and any therapeutic presence during the acute psychedelic state. This delimitation makes it possible to bring into ordinary psychotherapy knowledge about harm reduction, non-ordinary states of consciousness and integration processes without turning the therapist into a provider of a psychedelic experience. The architecture retains the distinction between preparation, experience and integration, although the PHRI intervention is located in preparation and integration and may begin directly after an experience that has already taken place. (Gorman et al., 2021, Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice; Hu, Gorman & Nielson, 2026, Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice).
-
Harm reduction shifts the focus from abstinence to the person's actual relationship with psychedelics
PHRI inherits from harm reduction psychotherapy the decision to start where the person is and to understand use within its biological, psychological, relational, social and cultural context. The clinical goal is not defined in advance as abstinence, nor is psychedelic use presumed to constitute a substance use disorder; motivations, functions, benefits, harms, ambivalences and specific risks are studied and goals are built together with the patient. Abstinence may appear as a chosen option where it reduces harm or answers the person's goals, but it does not function as a requirement for access to help. (Tatarsky & Marlatt, 2010, State of the Art in Harm Reduction Psychotherapy; Tatarsky & Kellogg, 2010, Integrative Harm Reduction Psychotherapy; Gorman et al., 2021).
-
The patient's autonomy is part of both the clinical mechanism and the ethical safeguard
The model reorganises the distribution of authority in the consulting room: the therapist accompanies, informs and formulates, while the person retains authorship over what they share, what meaning they attribute to their experience and what decisions they take. Non-directiveness, consent before suggesting and inquiry limit suggestion in a field where experiences may acquire a noetic quality or an extraordinary intensity of meaning and where the therapist may be idealised as an authority. Autonomy protects against iatrogenic dynamics and at the same time helps change to be sustained as the person's own choice. (Gorman et al., 2021, Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice; Hu, Gorman & Nielson, 2026).
-
Preparation and integration form a clinical continuum even though the acute experience lies outside PHRI
Preparation alters the quality of the subsequent process, because it clarifies motivations and expectations, identifies vulnerabilities, places the experience within a framework of risks and prepares supports and re-entry resources; integration then takes up what actually happened and relates it to ordinary life. The two phases inform each other and adapt to changing needs, while the phase of acute effects remains outside the PHRI intervention. This organisation makes it possible to work both with someone consulting before a possible experience and with someone arriving afterwards without having had any preparation. (Gorman et al., 2021; Hu, Gorman & Nielson, 2026).
-
Set, setting and context prevent the experience from being reduced to an isolated pharmacological effect
PHRI holds that the outcome of a psychedelic experience depends on the interaction between the compound, the person's psychological and biographical state, the physical environment, expectations, relationships and the cultural framework. Research on safety and challenging experiences shows that preparation, interpersonal support and environmental conditions are associated with meaningful differences in risk and difficulty, which justifies a contextual formulation. Integration asks about these components in order to understand what happened and to reduce future simplistic attributions of the "the drug did everything" kind. (Johnson, Richards & Griffiths, 2008, Human hallucinogen research: Guidelines for safety; Carbonaro et al., 2016; Gorman et al., 2021).
-
Meaning develops through inquiry, not through imposed interpretation
Psychedelic experiences may feel charged with meaning, but PHRI avoids equating subjective intensity with a truth the therapist must confirm or decipher. Inquiry directs attention to the concrete experience, uses listening, reflection and open questions, and trusts the person to develop an understanding of their own; non-directiveness reduces the risk that the therapist's theory, spirituality or personal experience will colonise the patient's material. Clinically useful meaning is meaning that can be examined, contextualised and related to the person's life without depending on the professional's interpretive authority. (Gorman et al., 2021; Bathje, Majeski & Kudowor, 2022, Psychedelic integration: An analysis of the concept and its practice).
-
A challenging experience may contain harm, benefit or both and calls for clinical discrimination
PHRI avoids two opposing reductions: automatically pathologising subsequent distress and romanticising every difficult experience as healing. In the survey by Carbonaro and colleagues, a large majority of participants attributed some benefit to their most difficult psilocybin experience, while a minority reported risky behaviour, medical attention or persisting psychological difficulties; this coexistence requires assessing intensity, duration, functioning and risk case by case. The therapist can prudently normalise transient reactions and at the same time recognise trauma, persisting symptoms or decompensation requiring specific treatment. (Carbonaro et al., 2016; Gorman et al., 2021; Hu, Gorman & Nielson, 2026).
-
Acceptance and psychological flexibility offer a way of working with fear without requiring the experience to be viewed positively
When the person responds to memories, emotions or sensations with rigid control and avoidance, the attempt to escape can increase suffering and block working through. PHRI uses principles compatible with mindfulness and ACT to encourage gradual contact, curiosity and the capacity to stay with the experience within a tolerable range, and then links that increased flexibility to chosen actions. ACT functions here as a useful framework and not as a doctrinal requirement of the model, and acceptance is aimed at being able to relate to what happened without requiring the person to regard it as beneficial. (Gorman et al., 2021; Hu, Gorman & Nielson, 2026).
-
Ego dissolution is integrated by restoring continuity without adjudicating the metaphysical truth of the experience
A temporary alteration in the sense of self may be experienced as liberating, terrifying or ontologically destabilising. PHRI combines contemplative and psychodynamic perspectives so that the therapist can understand these phenomena without treating them as pathology from the outset and without turning their content into objective facts; the task is to restore orientation where necessary, give language to what was lived, explore how it alters beliefs and the sense of identity, and foster a continuity stable enough for everyday life. This stance protects both the subjective experience and clinical judgement. (Gorman et al., 2021; Hu, Gorman & Nielson, 2026).
-
Integration may go on unfolding long after the acute state has ended
PHRI conceives integration as a temporally open process in which emotions, memories, meanings and changes in sensitivity may appear in waves over weeks or months, and some understandings may only make sense much later. This time course justifies alternating stabilisation and exploration, tolerating uncertainty and avoiding pressure to produce an immediate explanation. The integration literature converges in describing an active process of revisiting, working through, translating and incorporating the experience, rather than a single subsequent debriefing. (Hu, Gorman & Nielson, 2026; Bathje, Majeski & Kudowor, 2022).
Influences
- Integrative Harm Reduction Psychotherapy (IHRP)
- Psychedelic-assisted psychotherapy
- Mindfulness-based interventions
- Relational psychodynamic psychotherapy
Key references
- Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021). Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Frontiers in Psychology, 12, 645246. DOI: 10.3389/fpsyg.2021.645246.
- Hu, X., Gorman, I., & Nielson, E. M. (2026). Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Current Topics in Behavioral Neurosciences, 77, 397–416. DOI: 10.1007/7854_2024_529. Published online 10 December 2024.
- Bathje, G. J., Majeski, E., & Kudowor, M. (2022). Psychedelic integration: An analysis of the concept and its practice. Frontiers in Psychology, 13, 824077. DOI: 10.3389/fpsyg.2022.824077.
- Tatarsky, A. (Ed.). (2002). Harm Reduction Psychotherapy: A New Treatment for Drug and Alcohol Problems. Northvale, NJ: Jason Aronson. ISBN 0-7657-0352-1. Edición original consultada; Gorman et al. (2021) citan la reimpresión de 2007 publicada en Lanham, MD.
- Tatarsky, A., & Marlatt, G. A. (2010). State of the Art in Harm Reduction Psychotherapy: An Emerging Treatment for Substance Misuse. Journal of Clinical Psychology: In Session, 66(2), 117–122. DOI: 10.1002/jclp.20672.
- Tatarsky, A., & Kellogg, S. (2010). Integrative Harm Reduction Psychotherapy: A Case of Substance Use, Multiple Trauma, and Suicidality. Journal of Clinical Psychology: In Session, 66(2), 123–135. DOI: 10.1002/jclp.20666.
- Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. DOI: 10.1177/0269881108093587.
- Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278. DOI: 10.1177/0269881116662634.
- Frymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022). The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences. Frontiers in Psychology, 13, 863247. DOI: 10.3389/fpsyg.2022.863247.